





FUND FEATURES: (Data as on 31st

July'21)

Category: Small Cap Fund

Monthly Avg AUM: ₹1,311.29 Crores

Inception Date: 25th February 2020

Fund Manager: Mr. Anoop Bhaskar

Benchmark: S&P BSE 250 SmallCap-

TRI

Exit Load:

1% if redeemed/switched out within 1 year from the date of allotment

Minimum SIP Amount: ₹100 and in multiples of ₹1 thereafter

SIP Frequency: Monthly

SIP Dates (Monthly): Investor may choose any day of the month except 29th, 30th and 31st as the date of instalment.

Options Available: The Scheme offer IDCW[®] Option & Growth Option. IDCW[®] Option under each Plan further offers of choice of Payout & Sweep facilities.

@Income Distribution cum capital withdrawal

IDFC EMERGING BUSINESSES FUND

(Small Cap Fund - An open ended equity scheme predominantly investing in small cap stocks)

- Fund focuses on building a diversified portfolio within the small cap segment.
- Portfolio will contain buy and hold strategies as well as opportunistic picks in the cyclical space.
- Fund may also look to participate in new businesses via IPOs.

FUND PHILOSOPHY*

The fund aims to identify and invest in companies with steady growth prospects, operating in industries with a stable growth visibility over the medium term – 2-4 years. The fund would be willing to pay higher valuation for companies with distinct segment leadership advantages and/or for companies operating in segments which are witnessing a boost of growth due to change in industry dynamics; regulatory changes / geographical shifts. While not eschewing completely, the fund aims to limit exposure to "deep" cyclicals and focus more on companies and sectors with secular growth outlook. Hence, the valuation metrics of the fund – P/E; EV/EBIDTA; EV/Sales may appear to be more expensive than the benchmark.

Consumer facing rather than B to B is another focus area of the fund. The fund aims to ensure participation in non-small caps as a measure of higher liquidity as well addressability for investing in sectors where size brings noticeable advantage – BFSI, for example. The fund aims to hold cash levels of upto 10% across time periods, both as a measure of liquidity as well as to capitalize on opportunistic investing. Lastly, rather than try to outperform the benchmark on the upside, the fund would aim to conserve capital by limiting downside during periods of drawdowns, a dominant (and painful) characteristic of small cap investing.

OUTLOOK

The S&P BSE Sensex Index and Nifty 50 Index ended the roller-coaster ride of the month almost flat (0.3%) in July. Mid and Small caps were up 3% and 8%, respectively; outperforming Large caps in July.

Earnings growth for Q1 FY22 also commenced. The earnings' results so far has depicted mixed trends - reflecting increasing margin pressure, moderation in top-line momentum, and an increase in retail NPAs for some banks. Moreover, the ongoing earnings season reflects a few key trends:

- i. The momentum of activity visible in the Jan-Mar 2021 quarter stalled during the Apr-Jun 2021 quarter due to the 2nd wave of the pandemic.
- ii. Management commentary post-Apr-Jun 2021 quarter is more muted about the near term, as worries of a 3rd wave and its impact on business continuity remains an open question.
- iii. The cycle of upgrades witnessed from the Sep 2020 quarter will take a breather with the current quarter. Earnings for FY22 will be marginally downgraded, while earnings for FY23 remain unimpacted.


While, we believe there are few headwinds which could provide near term break to growth in the form of rising fears of Covid-19 third wave and associated slow pace of unlocking of economy in progress.


Т	D	F	C
IDFC	MUT	UAL	FUND

Name of the Instrument	% to NAV	Name of the Instrument	% to NAV
Equity and Equity related Instruments	95.87%	Pharmaceuticals	4.389
Consumer Non Durables	13.71%	FDC	1.549
Radico Khaitan	4.60%	Gland Pharma	1.519
Balrampur Chini Mills	2.59%	Laurus Labs	1.33%
DCM Shriram	1.25%	Cement & Cement Products	3.619
Heritage Foods	1.17% 1.03%	Sagar Cements	1.96% 1.31%
DFM Foods		JK Lakshmi Cement	
Emami	0.85% ACC		0.35%
United Spirits	0.77%	Capital Markets	3.57%
Godfrey Phillips India	0.76%	Multi Commodity Exchange of India	2.069
Jyothy Labs	0.69%	UTI Asset Management Company	1.519
Software	11.45%	Pesticides	3.189
Birlasoft	3.23%	Rallis India	1.649
Cyient	2.34%	Heranba Industries	1.549
Zensar Technologies	2.20%	Banks	2.829
eClerx Services	2.03%	State Bank of India	1.569
Mastek	0.93%	Kotak Mahindra Bank	0.759
Tech Mahindra	0.72%	Suryoday Small Finance Bank	0.519
Industrial Products	10.89%	Healthcare Services	2.73%
Shaily Engineering Plastics	3.43%	Narayana Hrudayalaya	1.709
Graphite India	2.04%	Krishna Institute of Medical Sciences	1.039
Polycab India	1.59%	Auto	2.329
EPL	1.15%	Ashok Leyland	1.329
Carborundum Universal	1.13%	Tata Motors	0.999
Huhtamaki India	0.85%	Commercial Services	2.239
Kirloskar Brothers	0.70%	TeamLease Services	2.239
KSB	0.02%	Petroleum Products	1.849
Auto Ancillaries	8.05%	Gulf Oil Lubricants India	1.849
Wheels India	2.00%	Textiles - Cotton	1.759
Alicon Castalloy	1.91%	Nitin Spinners	1.069
GNA Axles	1.49%	Vardhman Textiles	0.699
Jamna Auto Industries	1.48%	Power	1.729
Automotive Axles	1.16%		
Chemicals	7.07%	Kalpataru Power Transmission	1.729
NOCIL	3.28%	Retailing	1.409
Navin Fluorine International	2.91%	V-Mart Retail	1.409
Chemcon Speciality Chemicals	0.87%	Finance	1.049
Consumer Durables	4.99%	JM Financial	0.739
Kajaria Ceramics	2.30%	Magma Fincorp	0.319
Mayur Uniquoters	1.15%	Construction Project	1.039
Cera Sanitaryware	0.95%	Power Mech Projects	1.039
Greenply Industries	0.59%	Telecom - Services	0.849
Leisure Services	4.77%	Bharti Airtel	0.849
Westlife Development	2.05%	Insurance	0.479
Jubilant Foodworks	1.01%	SBI Life Insurance Company	0.479
EIH	0.93%	Net Cash and Cash Equivalent	4.139
Burger King India	0.78%	Grand Total	4.137









Investors understand that their principal will be at Very High risk

This product is suitable for investors who are seeking*:

- To create wealth over long term
- · Investment in equity and equityr elated instruments of Small cap companies.

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.





